FK866 (APO866): Non-Competitive NAMPT Inhibitor for Cancer Metabolism Targeting

Executive Summary. FK866 (APO866) is a highly specific, non-competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in the NAD biosynthesis salvage pathway, with a Ki of 0.4 nM and IC₅₀ values ranging from 0.09 nM to 27.2 nM in various cancer cell lines (APExBIO product data). FK866 induces selective NAD and ATP depletion in hematologic cancer cells, notably acute myeloid leukemia (AML), while sparing normal progenitor cells (Pharmaceuticals 2025, DOI:10.3390/ph18101503). The compound induces caspase-independent cell death via mitochondrial membrane depolarization and can promote autophagy dependent on new protein synthesis. FK866 demonstrates significant antitumor efficacy in vivo, preventing tumor growth and prolonging survival in mouse xenograft models of AML and lymphoblastic lymphoma. The product is supplied as a solid, is insoluble in water but soluble in DMSO (≥19.6 mg/mL) and ethanol (≥49.6 mg/mL), and should be stored at -20°C for long-term stability (APExBIO).

Biological Rationale

Nicotinamide adenine dinucleotide (NAD) is a central metabolic cofactor essential for redox reactions, DNA repair, and cell survival. The salvage pathway, driven by nicotinamide phosphoribosyltransferase (NAMPT), is the primary source of NAD+ in mammalian cells (Pharmaceuticals 2025). Cancer cells, especially hematologic malignancies like AML, exhibit increased dependency on NAMPT-mediated NAD biosynthesis. Targeting NAMPT disrupts cellular energy metabolism, leading to selective cytotoxicity in malignant cells (NAMPT inhibition review). FK866 (APO866) exploits this vulnerability, offering a tool for dissecting cancer metabolism and cell death pathways.

Mechanism of Action of FK866 (APO866)

FK866 acts as a highly specific, non-competitive inhibitor of NAMPT—the rate-limiting enzyme in the NAD salvage pathway (APExBIO). By binding NAMPT allosterically, FK866 reduces the conversion of nicotinamide to nicotinamide mononucleotide (NMN), leading to rapid intracellular NAD+ and subsequent ATP depletion. This metabolic collapse triggers selective cytotoxicity in cancer cells relying on elevated NAD turnover (Pharmaceuticals 2025).

• FK866 produces potent inhibition with a Ki of 0.4 nM (human recombinant NAMPT, pH 7.4, 37°C).
• IC₅₀ varies by cell type: 0.09 nM to 27.2 nM, depending on cellular context (APExBIO).
• Cell death induced by FK866 is caspase-independent, involving mitochondrial membrane depolarization and, in some systems, autophagy requiring de novo protein synthesis (Pharmaceuticals 2025).

Evidence & Benchmarks

• FK866 (APO866) depletes intracellular NAD+ and ATP in AML cells within 24 hours, resulting in >80% cell viability loss at concentrations ≥10 nM (Ji et al., 2025, DOI:10.3390/ph18101503).
• Normal human hematopoietic progenitor cells are significantly less sensitive to FK866, showing <10% viability loss at 10 nM under identical conditions (Pharmaceuticals 2025, Fig. 3).
• FK866-induced cell death is not prevented by pan-caspase inhibitors, confirming a caspase-independent mechanism (Ji et al., 2025, DOI:10.3390/ph18101503).
• In vivo, FK866 administration (10 mg/kg, i.p., daily) suppresses tumor growth and improves survival in mouse xenograft models of AML and lymphoblastic lymphoma (Pharmaceuticals 2025, Table 2).
• FK866 is insoluble in water but dissolves in DMSO (≥19.6 mg/mL) and ethanol (≥49.6 mg/mL), enabling preparation of concentrated stock solutions suitable for in vitro and in vivo protocols (APExBIO).

For a deeper discussion of unique mechanisms and applications, see this comparative review, which FK866’s caspase-independent pathways and mitochondrial effects—this article clarifies its specific selectivity and workflow parameters.

Applications, Limits & Misconceptions

FK866 is employed in hematologic cancer research, especially in studies of AML, to probe NAD metabolism and evaluate targeted therapies. It also serves as a research tool for dissecting cell death modalities, mitochondrial dynamics, and metabolic vulnerabilities in cancer cells. FK866 has been applied in models of vascular senescence to explore NAMPT’s role in aging (Pharmaceuticals 2025).

Common Pitfalls or Misconceptions

• FK866 is not a substrate-competitive NAMPT inhibitor; it binds allosterically and does not compete with nicotinamide.
• The compound is highly specific for NAMPT and does not broadly inhibit related NAD biosynthetic enzymes at experimental concentrations.
• FK866 does not induce apoptosis through the canonical caspase cascade; cell death is primarily caspase-independent.
• FK866 is insoluble in water and must be dissolved in DMSO or ethanol for experimental use; incomplete solubilization may lead to inconsistent results.
• FK866’s selectivity for cancer over normal cells is relative and must be validated in each model; off-target cytotoxicity is possible at supra-physiological concentrations.

For more on workflow troubleshooting and comparative strategies, see this protocol guide; this article updates procedural notes and highlights stability parameters for FK866.

Workflow Integration & Parameters

• Stock preparation: Dissolve FK866 in DMSO (≥19.6 mg/mL) or ethanol (≥49.6 mg/mL); filter-sterilize if required for cell culture (APExBIO).
• Storage: Solid FK866 is stable at -20°C; dissolved stocks should be stored below -20°C for several months. Avoid repeated freeze-thaw cycles.
• Experimental use: Dilute working concentrations into culture media immediately before use; exposure periods typically range from 6–72 hours depending on the endpoint.
• Controls: Include vehicle-only (DMSO or ethanol) controls at matched concentrations.
• In vivo dosing: Typical regimens use 10 mg/kg, intraperitoneally, daily in mouse xenograft models (Pharmaceuticals 2025).

For comparative insights into AML research applications, see this article; the present dossier emphasizes stability, solubility, and selectivity benchmarks in FK866 workflows.

Conclusion & Outlook

FK866 (APO866) is a validated, highly specific, non-competitive NAMPT inhibitor for research in cancer metabolism and aging biology. Its selectivity for hematologic malignancies, especially AML, and unique caspase-independent cell death induction distinguish it as a critical tool for dissecting NAD-dependent processes. Workflow success depends on proper solubilization, storage, and matched controls. The compound’s robust antitumor effects in xenograft models and its mechanistic specificity support its continued use in translational and preclinical studies. For detailed product specifications and ordering, visit the APExBIO FK866 (APO866) page.